Patents by Inventor Cendrine Lemoine

Cendrine Lemoine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416395
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: April 14, 2023
    Publication date: December 28, 2023
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • Publication number: 20230391888
    Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Application
    Filed: March 17, 2023
    Publication date: December 7, 2023
    Inventors: Christian Beil, Karl-Christian Engel, Gerhard Hessler, Soraya Hoelper, Christian Lange, Thomas Langer, Cendrine Lemoine, Wulf-Dirk Leuschner, Sevim Ozgur Bruderle, Ercole Rao, Nadja Spindler, Sandra Weil
  • Publication number: 20230357401
    Abstract: The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.
    Type: Application
    Filed: November 11, 2022
    Publication date: November 9, 2023
    Inventors: Lan WU, Ling XU, Edward SEUNG, Ronnie WEI, Gary NABEL, Zhi-Yong YANG, Tarik DABDOUBI, Béatrice CAMERON, Cendrine LEMOINE, Catherine PRADES
  • Publication number: 20230303704
    Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.
    Type: Application
    Filed: October 12, 2022
    Publication date: September 28, 2023
    Inventors: Yves SABBAGH, Yangde CHEN, William BRONDYK, Huawei QIU, Sunghae PARK, Ronnie WEI, Yu QIU, Yanfeng ZHOU, Cendrine LEMOINE, HyunSuk CHO
  • Patent number: 11739160
    Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 29, 2023
    Assignee: SANOFI
    Inventors: Christian Beil, Karl-Christian Engel, Gerhard Hessler, Soraya Hoelper, Christian Lange, Thomas Langer, Cendrine Lemoine, Wulf-Dirk Leuschner, Sevim Ozgur Bruderle, Ercole Rao, Nadja Spindler, Sandra Weil
  • Patent number: 11655302
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 23, 2023
    Assignee: SANOFI
    Inventors: Marielle Chiron Blondel, Cendrine Lemoine, Angela Virone-Oddos, Béatrice Cameron, Jacques Dumas, Alain Fournier, Jonathan Kingsbury, Brian Murray, Nathan Ostberg, Sanket Patke, Zichuan Zhang
  • Patent number: 11613576
    Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: March 28, 2023
    Assignee: SANOFI
    Inventors: Christian Beil, Jochen Beninga, Joerg Birkenfeld, Gary J. Nabel, Huawei Qiu, Ercole Rao, Joerg Regula, Edward Seung, Ronnie Wei, Lan Wu, Zhen Xing, Ling Xu, Zhi-Yong Yang, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
  • Patent number: 11530268
    Abstract: The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: December 20, 2022
    Assignee: Sanofi
    Inventors: Lan Wu, Ling Xu, Edward Seung, Ronnie Wei, Gary Nabel, Zhi-Yong Yang, Tarik Dabdoubi, Béatrice Cameron, Cendrine Lemoine, Catherine Prades
  • Patent number: 11505611
    Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: November 22, 2022
    Assignee: GENZYME CORPORATION
    Inventors: Yves Sabbagh, Yangde Chen, William Brondyk, Huawei Qiu, Sunghae Park, Ronnie Wei, Yu Qiu, Yanfeng Zhou, Cendrine Lemoine, HyunSuk Cho
  • Publication number: 20220275063
    Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.
    Type: Application
    Filed: February 16, 2022
    Publication date: September 1, 2022
    Inventors: Kara CARTER, Cendrine LEMOINE, Marie MANDRON, Sunghae PARK, Huawei QIU, Jonathan ROTHBLATT
  • Publication number: 20220275102
    Abstract: The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 1, 2022
    Inventors: Béatrice CAMERON, Tarik DABDOUBI, Cendrine LEMOINE, Catherine PRADES
  • Patent number: 11365261
    Abstract: The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: June 21, 2022
    Assignee: SANOFI
    Inventors: Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
  • Patent number: 11286295
    Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: March 29, 2022
    Assignee: SANOFI
    Inventors: Kara Carter, Cendrine Lemoine, Marie Mandron, Sunghae Park, Huawei Qiu, Jonathan Rothblatt
  • Publication number: 20220056142
    Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.
    Type: Application
    Filed: August 20, 2021
    Publication date: February 24, 2022
    Inventors: Yves SABBAGH, Yangde CHEN, William BRONDYK, Huawei QIU, Sunghae PARK, Ronnie WEI, Yu QIU, Yanfeng ZHOU, Cendrine LEMOINE, HyunSuk CHO
  • Publication number: 20220041746
    Abstract: The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 10, 2022
    Inventors: Béatrice CAMERON, Tarik DABDOUBI, Cendrine LEMOINE, Catherine PRADES
  • Patent number: 11186649
    Abstract: The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: November 30, 2021
    Assignee: Sanofi
    Inventors: Lan Wu, Ling Xu, Edward Seung, Ronnie Wei, Gary Nabel, Zhi-Yong Yang, Tarik Dabdoubi, Béatrice Cameron, Cendrine Lemoine, Catherine Prades
  • Publication number: 20210292423
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: January 12, 2021
    Publication date: September 23, 2021
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • Publication number: 20210260165
    Abstract: The invention relates to methods of treating a hepatitis B virus (HBV) infection in a subject in need thereof, comprising administering to the subject a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist (e.g., a an agonistic antibody directed against the receptor, a soluble TNFRSF agonist including but not limited to its natural ligand or a fragment of either) and an interferon (IFN) or a functional fragment thereof, to decrease one or more symptoms of HBV infection in the subject are provided.
    Type: Application
    Filed: May 31, 2019
    Publication date: August 26, 2021
    Inventors: Antoine ALAM, Odile BONNIN, Kara CARTER, Julie MONTEGUT, Cendrine LEMOINE, Xavier MARNIQUET
  • Patent number: 10906978
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: February 2, 2021
    Assignee: SANOFI
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • Publication number: 20200399369
    Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 8, 2020
    Publication date: December 24, 2020
    Inventors: Mangaiarkarasi ASOKAN, Christian BEIL, Jochen BENINGA, Joerg BIRKENFELD, Mark CONNORS, Richard A. KOUP, Young Do KWON, Peter D. KWONG, Qingbo LIU, Paolo LUSSO, John R. MASCOLA, Gary J. NABEL, Amarendra PEGU, Huawei QIU, Ercole RAO, Joerg REGULA, Edward SEUNG, Ronnie WEI, Lan WU, Zhen XING, Ling XU, Zhi-Yong YANG, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades